Browsing by Author "Eren M."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure
    (2013) Velibey Y.; Golcuk Y.; Golcuk B.; Oray D.; Atilla O.D.; Colak A.; Kurtulmus Y.; Erbay A.R.; Yilmaz A.; Eren M.
    Objective The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED). To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis. Methods NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED. The end point was survival from the time of inclusion through 4 years. Results The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female. During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs72.83 ± 11.07 years, P =.002). The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P =.044). Conclusion Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission. Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity. However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results. © 2013 Elsevier Inc.
  • No Thumbnail Available
    Item
    Familial mediterranean fever mutation analysis in pediatric patients with İnflammatory Bowel Disease: A multicenter study
    (AVES, 2021) Urganci N.; Ozgenc F.; Kuloǧlu Z.; Yüksekkaya H.; Sari S.; Erkan T.; Önal Z.; Çaltepe G.; Akçam M.; Arslan D.; Arslan N.; Artan R.; Aydoǧan A.; Balamtekin N.; Baran M.; Baysoy G.; Çakir M.; Dalgiç B.; Doǧan Y.; Durmaz O.; Ecevit C.; Eren M.; Gökçe S.; Gülerman F.; Gürakan F.; Hizli S.; Işik I.; Kalayci A.G.; Kansu A.; Kutlu T.; Karabiber H.; Kasirga E.; Kutluk G.; Hoşnut F.O.; Özen H.; Özkan T.; Öztürk Y.; Soylu O.B.; Tutar E.; Tümgör G.; Ünal F.; Ugraş M.; Üstündaǧ G.; Yaman A.
    Background: The aim of the study was to evaluate familial Mediterranean fever (FMF) mutation analysis in pediatric patients with inflammatory bowel disease (IBD). The relation between MEFV mutations and chronic inflammatory diseases has been reported previously. Methods: Children with IBD (334 ulcerative colitis (UC), 224 Crohn's disease (CD), 39 indeterminate colitis (IC)) were tested for FMF mutations in this multicenter study. The distribution of mutations according to disease type, histopathological findings, and disease activity indexes was determined. Results: A total of 597 children (mean age: 10.8 ± 4.6 years, M/F: 1.05) with IBD were included in the study. In this study, 41.9% of the patients had FMF mutations. E148Q was the most common mutation in UC and CD, and M694V in IC (30.5%, 34.5%, 47.1%, respectively). There was a significant difference in terms of endoscopic and histopathological findings according to mutation types (homozygous/ heterozygous) in patients with UC (P < .05). There was a statistically significant difference between colonoscopy findings in patients with or without mutations (P = .031, P = .045, respectively). The patients with UC who had mutations had lower Pediatric Ulcerative Colitis Activity Index (PUCAI) scores than the patients without mutations (P = .007). Conclusion: Although FMF mutations are unrelated to CD patients, but observed in UC patients with low PUCAI scores, it was established that mutations do not have a high impact on inflammatory response and clinical outcome of the disease. Copyright © 2021 by The Turkish Society of Gastroenterology.